Time-Restricted Eating Early in Day More Effective for Weight Loss
Time-restricted eating from 7:00 to 15:00 more effective for weight loss, reducing diastolic BP than control with energy restriction
Metabolic Disorders
Patisiran Promising for Transthyretin-Mediated Amyloidosis With Cardiomyopathy
The APOLLO-B study included patients 18 years of age and older with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy.
USPSTF Still Says Individualize Decision for Diet, Exercise Counseling
Behavioral counseling interventions have small net benefit on CVD risk in adults without CVD risk factors
Obesity Up in US Children, Teens From 2011 to 2020
Increases seen across all races, boys and girls, and most ages
MPR Weekly Dose Podcast #122
New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.
Qsymia Approved for Chronic Weight Management in Pediatric Patients
The approval was based on data from a phase 4 study which included patients 12 to 17 years of age with a BMI at the 95th percentile or greater standardized for age and sex.
Eplontersen Bests Placebo in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Study
Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.
Imcivree Approved for Weight Management in Bardet-Biedl Syndrome
Imcivree is a melanocortin 4 receptor (MC4R) agonist that re-establishes MC4 receptor pathway activity to reduce hunger and promote weight loss.
Little Difference Seen in Weight Changes Before, After COVID-19 Shutdown
Significant increases seen in weight during preshutdown and postshutdown years, but no significant difference noted between the two
